The 10% mindset and power of bold ideas | Prof. Dr. Dominik Ruettinger, Global Head Oncology R&D, Bayer Pharmaceuticals
Nucleate PodcastShow Notes
In this episode of the Nucleate Podcast, we are joined by Prof. Dr. Dominik Rüttinger — oncological surgeon, MD/PhD, and Global Head of Research & Early Development Oncology at Bayer Pharmaceuticals. We talk about his journey from the operating room to biotech startups and global pharma leadership, navigating a 10% success rate in oncology drug development, building unbiased decision frameworks for high-stakes calls, the realistic role of AI in drug discovery and clinical trials, balancing quality of life versus longevity in cancer treatment, and his vision for the future of prevention, early detection, and personalized medicine. Whether you’re a scientist, innovator, or leader, this conversation will challenge how you think about risk, decision-making, and impact in healthcare.
Episode Chapters: 00:00 Intro 02:30 Dominik talks about his childhood, family background, and early influences that led him toward science 04:45 Dominik explains his decision to pursue both medicine and science, describing how his medical school and PhD experiences overlapped 07:30 Offering early career advice, Dominik talks about the importance of aiming high, questioning the status quo, and embracing a bit of naivete 11:06 Dominik discusses why he chose oncology and how interdisciplinary training shaped his career 16:45 Dominik describes his transition from academia to industry, sharing his motivations and the decision-making process behind the move 20:02 Reflecting on his adjustment to industry, Dominik highlights the differences in work environment and expectations compared to academia 23:33 Dominik provides practical tips for others transitioning from academia to industry, emphasizing humility and the value of building a diverse “toolbox” of skills 28:01 Dominik talks about moving from a startup to a large company, and how his responsibilities shifted to managing a broader portfolio 33:28 Dominik describes what his daily life looks like as a portfolio leader in oncology R&D and the types of decisions he makes regularly 37:24 Dominik delves into the challenges of decision-making in drug development, discussing success rates and the importance of a “10% mindset.” 39:27 Dominik explains the impact of biases in drug development and how organizations use frameworks to make more objective decisions 42:46 Dominik shares his perspective on the role of AI in drug development and how it can support better decision-making 47:02 Dominik discusses the use of AI in clinical trials and considers whether it can make development faster and less expensive 51:46 Drawing on his clinical experience, Dominik talks about patient care and patient perspectives, especially the balance between quality of life and longevity in cancer treatment 55:38 Dominik looks to the future of cancer prevention, early detection, and prediction, and how these areas might evolve
More from Nucleate Podcast
The Nucleate Podcast welcomes Matias Serebrinsky, co-founder of Psymed Ventures. Raised in Argentina by a physician father and an economist mother, he shares how his early life influenced his comfort with risk and his drive to do work that helps others. Matias shares his path from Sony marketing to starting CookUnity, and eventually to building a venture fund focused on brain and mental health.
In this episode of the Nucleate Podcast, Dr. Jo Viney, co-founder, president, and CEO of Seismic Therapeutic, shares her trajectory from academic immunology training in London to major biotech companies and startup leadership. She discusses how early clinical lab exposure to autoimmune patients sparked her passion for translational science and highlights why the Boston ecosystem is an ideal place to launch biotech startups due to its unparalleled funding, incubator space, and collaborative peer networks. She also reflects on the lessons learned from co-funding Pandion Therapeutics—including how following surprising data led to a major asset acquisition by Merck—and describes the bittersweet feeling of handing off a company she helped build.
In this episode of the Nucleate Podcast, Joe Betts-LaCroix, co-founder of Retro Biosciences, traces his path from Silicon Valley hardware startups to longevity biotech, explaining that a liquidity event from his first company prompted him to reflect on the limited real-world impact of most tech products compared to medicine, which almost always meaningfully helps people. He describes Retro's approach to navigating biotech regulation through a "daughter test" – asking whether a given regulatory requirement is one he'd genuinely want applied if it were his own family member's treatment on the line. He then explains why the company has set an ambitious but achievable mission of extending healthy human lifespan by 10 years, framing it as a "right-sized" goal for a venture-backed startup.
She started out as a small-town GP in South Africa with zero idea a "biotech industry" even existed. Three decades later, Deborah Dunsire had led the launch of Gleevec — the first targeted cancer therapy ever approved — steered Millennium Pharmaceuticals through an $8.8 billion acquisition, and run two more companies through drug failures, board showdowns, and billion-dollar bets. In this episode, she takes us inside the moments that don't make the press release: a phase one cancer patient still alive today, decades after a drug nobody thought would work; a multiple myeloma patient who happened to be trial patient #007 and was actually named James Bond; and the $60,000 milk-budget cut that nearly tanked employee morale company-wide.
In this episode of the podcast we are joined by Dr. Phillip Sharp, Nobel Prize Laureate and Institute Professor at MIT, who shares his story behind the groundbreaking discovery of RNA splicing. He explains how the work ethic and problem solving instinctions he built early on eventually led him to Caltech, and then MIT, where his 1977 discovery changed how we understand gene expression.